Updated:
PMV Pharmaceuticals
PMV Pharmaceuticals, co-founded by p53 discoverer Arnold Levine, designs mutant-specific correctors for the tumor suppressor.
PMV Pharmaceuticals
PMV Pharmaceuticals was co-founded in 2013 by Dr. Arnold J. Levine, the scientist who discovered the p53 tumor suppressor protein in 1979. The company operates from Princeton, New Jersey, and went public on the Nasdaq in September 2020 under the ticker PMVP. Its foundational thesis is that small molecules can be designed to correct specific misfolded p53 mutants, restoring the protein's natural ability to suppress tumor growth across a broad range of cancers. The firm's discovery platform relies on a proprietary computational and structural biology engine to screen p53 hotspot mutations and identify druggable pockets. PMV has advanced a pipeline of mutant-p53 reactivators into clinical trials, with lead asset PC14586 targeting the Y220C mutation (per the firm, 2023). The pipeline spans solid tumor indications including ovarian, breast, and colorectal cancers. The company has not disclosed a multi-asset-class investment posture, as its capital allocation is singularly directed toward in-house drug development rather than external fund commitments or venture-style portfolio construction. In October 2023, PMV reported updated Phase 1/2 clinical data for PC14586 demonstrating a 38% confirmed overall response rate in heavily pretreated Y220C-mutant patients (per the company, October 2023). The firm, which employed roughly 70 staff at the close of 2023, has not launched adjacent vehicles, philanthropic foundations, or co-investor clubs. Its operational scale is that of a clinical-stage biotech, not a diversified investment firm. Top institutional shareholders as of early 2024 included OrbiMed, RA Capital Management, and Boxer Capital (per SEC filings, 2024). The firm's structural distinction lies in its mutation-by-mutation approach to p53. Unlike immuno-oncology platforms or broad-spectrum chemotherapies, PMV's portfolio is a collection of mutant-specific correctors, each requiring a bespoke small molecule. This architecture makes the pipeline both molecularly precise and clinically narrow, a dual constraint that defines both the company's scientific identity and its commercial risk profile.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Princeton
Corporate office
Princeton, NJ, United States
Principals
David Mack
Chief Executive Officer
Arnold J. Levine
Co-Founder and Chair of the Scientific Advisory Board
Sector focus
Frequently asked questions
Who discovered the p53 target that PMV's platform is built around?
Dr. Arnold J. Levine, PMV's co-founder, discovered the p53 tumor suppressor protein in 1979 during his tenure at Princeton University. The company's entire precision oncology strategy derives from Levine's structural biology work on how missense mutations cause p53 to misfold and lose its tumor-suppressing function.
What is PMV's lead clinical asset and which mutation does it target?
PC14586 is a first-in-class small molecule reactivator designed for the p53 Y220C hotspot mutation. As of October 2023, the company reported a 38% confirmed overall response rate in a heavily pretreated patient population. The drug is dosed orally once daily and is in Phase 1/2 development across multiple solid tumor types including ovarian, breast, and colorectal cancers.
Is PMV Pharmaceuticals a single-family office or an investment firm?
Neither. PMV Pharmaceuticals is a publicly traded clinical-stage biotechnology company listed on the Nasdaq under the ticker PMVP. It does not manage third-party capital or operate as a family office — it is an operating drug discovery and development company funded by venture capital prior to its 2020 IPO.
How is PMV's approach to oncology structurally different from immunotherapy platforms?
PMV targets the p53 protein directly, correcting specific missense mutations that cause misfolding, rather than modulating the immune system. Each mutation requires a bespoke small molecule, creating a pipeline built on molecular precision rather than platform scalability. This mutation-by-mutation architecture is precise but narrow: success in Y220C does not automatically translate to other p53 mutants.
Who are PMV's largest institutional shareholders?
Based on SEC 13F filings in early 2024, top institutional stakeholders included OrbiMed Advisors, RA Capital Management, and Boxer Capital. These specialized healthcare funds held concentrated positions following the company's 2020 IPO and subsequent clinical data readouts.
Does PMV operate any philanthropic or investment vehicles outside of drug development?
No. As of the latest public disclosures, PMV Pharmaceuticals has not established a foundation, a family office structure, or any adjacent investment vehicles. The company's entire operational footprint is directed toward advancing its internal pipeline of p53 reactivators.
What stage cancer patients is PMV enrolling in its PC14586 clinical trials?
The Phase 1/2 PYNNACLE trial is enrolling patients with advanced solid tumors harboring the p53 Y220C mutation who have progressed on or after standard-of-care therapies. The patient populations are heavily pretreated, and the company is enrolling multiple tumor types in parallel expansion cohorts.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: